CN112262982A - 一种化疗后辅助修复消化道粘膜的功能性食品及其应用 - Google Patents
一种化疗后辅助修复消化道粘膜的功能性食品及其应用 Download PDFInfo
- Publication number
- CN112262982A CN112262982A CN202011141422.2A CN202011141422A CN112262982A CN 112262982 A CN112262982 A CN 112262982A CN 202011141422 A CN202011141422 A CN 202011141422A CN 112262982 A CN112262982 A CN 112262982A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- chemotherapy
- digestive tract
- functional food
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 38
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 32
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 28
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 20
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000011575 calcium Substances 0.000 claims abstract description 13
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 13
- 239000011777 magnesium Substances 0.000 claims abstract description 13
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 13
- 239000011591 potassium Substances 0.000 claims abstract description 13
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 13
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 12
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 12
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 10
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001231 choline Drugs 0.000 claims abstract description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052802 copper Inorganic materials 0.000 claims abstract description 10
- 239000010949 copper Substances 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 10
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 10
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 10
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 10
- 239000011669 selenium Substances 0.000 claims abstract description 10
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 10
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 10
- 239000011701 zinc Substances 0.000 claims abstract description 10
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 10
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002685 biotin Drugs 0.000 claims abstract description 9
- 239000011616 biotin Substances 0.000 claims abstract description 9
- 235000020958 biotin Nutrition 0.000 claims abstract description 9
- 229960000367 inositol Drugs 0.000 claims abstract description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 9
- 229910052742 iron Inorganic materials 0.000 claims abstract description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000008439 repair process Effects 0.000 claims abstract description 8
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 8
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract 2
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- 229910052748 manganese Inorganic materials 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 235000001055 magnesium Nutrition 0.000 abstract description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 10
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 239000011709 vitamin E Substances 0.000 abstract description 3
- 229940045997 vitamin a Drugs 0.000 abstract description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 229960002743 glutamine Drugs 0.000 abstract description 2
- 235000004554 glutamine Nutrition 0.000 abstract description 2
- 235000019155 vitamin A Nutrition 0.000 abstract description 2
- 239000011719 vitamin A Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 229960003975 potassium Drugs 0.000 description 10
- 235000007686 potassium Nutrition 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004347 intestinal mucosa Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229930192392 Mitomycin Natural products 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 229960004857 mitomycin Drugs 0.000 description 7
- 229940091258 selenium supplement Drugs 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 101150086731 ges-1 gene Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000015735 Beta-catenin Human genes 0.000 description 4
- 108060000903 Beta-catenin Proteins 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- LOZUXFQXMUUIGR-UHFFFAOYSA-N [5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl pyridine-3-carboxylate Chemical compound OCC1=C(O)C(C)=NC=C1COC(=O)C1=CC=CN=C1 LOZUXFQXMUUIGR-UHFFFAOYSA-N 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- -1 compound vitamin Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101001000747 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2A Proteins 0.000 description 2
- 101001000734 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2B Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NCYSTSFUYSFMEO-OBLTVXDOSA-N PGI3 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C\C=C/CC)[C@H](O)C[C@@H]21 NCYSTSFUYSFMEO-OBLTVXDOSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 208000037817 intestinal injury Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical group [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000012339 Real-time fluorescence quantitative polymerase chain reaction Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NMZKLLJQNNTBRJ-OIXZZONUSA-N TXA3 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)C\C=C/CC)O[C@@H]2O[C@H]1C2 NMZKLLJQNNTBRJ-OIXZZONUSA-N 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical group [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical group [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940052714 riboflavin 1 mg Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical group [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种化疗后辅助修复消化道粘膜的功能性食品，包括：低聚半乳糖、水苏糖、低聚甘露糖、谷氨酰胺、维生素A、维生素D3、维生素E、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、烟酸、叶酸、泛酸、生物素、胆碱、肌醇、钙、钾、镁、铁、锌、碘、硒、铜、锰、DHA、EPA、omega‑3、磷脂酰丝氨酸；该功能性食品可以有效修复消化道道屏障，提高肿瘤患者的免疫力，有效降低了化疗后化疗药物对消化道的副作用。
Description
技术领域
本发明涉及功能性食品技术领域，更具体地说是涉及一种化疗后辅助修复消化道粘膜的组合物及其应用。
背景技术
化疗是化学药物治疗的简称，是利用化学药物阻止癌细胞的增殖、浸润、转移，直至最终杀灭癌细胞的一种治疗方式。它是一种全身性治疗手段，和手术、放疗一起，并称为癌症的三大治疗手段。由于化疗药物的选择性不强，在杀灭癌细胞的同时也会不可避免地损伤人体正常的细胞，从而出现药物的不良反应。因此，在接受化疗药物的时候，一方面希望能够达到最佳的抗肿瘤作用，另一方面也要注意预防和识别化疗药物的不良反应。
功能性食品是指具有特定功能的食品，适宜于特定人群食用，可调节机体的功能，又不以治疗为目的，在化疗过程中，最常见的就是恶心、呕吐等消化道反应。
胃肠道粘膜细胞和骨髓细胞同属增殖型细胞，具有高度生长功能，所以，胃肠道粘膜细胞对化疗药物均敏感，在用药数小时内即可出现毒性反应。胃肠道反应，可直接由药物刺激引起，也可由于药物对消化道粘膜修补增生抑制引起；还有一部分是通过非自主神经系统而引起。胃肠道不良反应可以是食欲减退、恶心、呕吐、腹痛、便秘、腹泻、甚至是血性腹泻，严重破坏肠道屏障；若能够研发一种功能性食品使其能够辅助修复肠道粘膜，缓解化疗后带来的副作用，就可减少肿瘤患者的痛苦。
因此，如何提供一种化疗后辅助修复消化道粘膜的功能性食品是本领域技术人员亟需解决的问题。
发明内容
有鉴于此，本发明提供了一种化疗后辅助修复消化道粘膜的功能性食品，其可以有效修复消化道黏膜屏障，提高肿瘤患者的免疫力，有效降低化疗药物对消化道的副作用。
为了实现上述目的，本发明采用如下技术方案：
一种化疗后辅助修复消化道粘膜的功能性食品，包括：低聚半乳糖0.2-0.5g、水苏糖0.5-2g、低聚甘露糖0.1-0.3g、谷氨酰胺0.8-1.3g、维生素A 100-300μgRE、维生素D32.5-3.5μg、维生素E1.6-10mgα-TE、维生素B10.25-1mg、维生素B20.25-1mg、维生素B60.2-1mg、维生素B120.3-3μg、维生素C 20-65mg、烟酸2.2-5mg、叶酸60-70μg、泛酸1-3.5mg、生物素10-30μg、胆碱1-10mg、肌醇1-10mg、钙30-140mg、钾10-15mg、镁10-40mg、铁2.0-3.0mg、锌2.5-3.5mg、碘20-25μg、硒10-17μg、铜0.15-0.27mg、锰0.5-0.7mg、DHA 50-60mg、EPA 75-90mg、omega-3135-150mg、磷脂酰丝氨酸7-10mg。
作为本发明优选的技术方案，所述功能性食品包括：低聚半乳糖0.3g、水苏糖0.8g、低聚甘露糖0.2g、谷氨酰胺1.0g、维生素A 215μgRE、维生素D33.0μg、维生素E 5.4mgα-TE、维生素B10.65 mg、维生素B20.65 mg、维生素B60.65 mg、维生素B120.15μg、维生素C40mg、烟酸3.5mg、叶酸66μg、泛酸2.0mg、生物素21μg、胆碱7.5mg、肌醇7.5mg、钙100mg、钾12.5mg、镁25mg、铁2.5mg、锌3.0mg、碘22μg、硒14.5μg、铜0.20mg、锰0.6mg、DHA 55mg、EPA85mg、omega-3142mg、磷脂酰丝氨酸8.5mg。
上述技术方案达到的技术效果是：
低聚半乳糖、水苏糖和低聚甘露糖是一种功能性低聚糖，食后不能被小肠吸收，直入大肠，被大肠中广泛存在的微生物菌群利用，发酵产生有机酸，降低肠道中的pH值，抑制腐败作用，促进双歧杆菌、乳酸菌等益生菌的生长和活性，从而起到与食用益生菌同样的健康效用，如能减预防便秘，抑制肿瘤的生长，促进矿物元素吸收等，并能刺激机体免疫功能；
谷氨酰胺是半必需氨基酸，可肠上皮细胞提高能量，维持肠道细胞正常的通透性；谷氨酰胺可能通过刺激肠黏膜IGF1、CLN和GLN合成酶mRNA表达，下调肠黏膜细胞凋亡，从而促进肠黏膜修复；此外，谷氨酰胺能促进黏膜淋巴组织分泌S-IgA，降低细菌对黏膜的附着和定植，防止其穿越肠黏膜上皮细胞层，以减少细菌和内毒素的易位；
维生素A被小肠吸收后，促进糖蛋白的合成，可提高机体的免疫功能，抑制肿瘤的生长，同时，能促进肠道细胞的增殖，降低化疗药物对肠道细胞增殖的抑制作用；
维生素D3提高肌体对钙、磷的吸收，使血浆钙和血浆磷的水平达到饱和程度，抑制结肠癌、乳腺癌、肺癌的发生；
维生素E可以调节自主神经系统，促进血液循环，因此可以促进胃肠道蠕动，防止便秘；
维生素B1可以促进儿童神经系统的发育，可维持正常的消化腺分泌和胃肠道蠕动从而促进消化，增强肿瘤患者的食欲；
维生素B2作为一种辅酶，可在一定程度上促进消化；
维生素B6参与蛋白质合成与分解代谢，参与所有氨基酸代谢；维生素B群、维生素B1、维生素B2、泛酸、维生素C、镁、钾、钠、亚麻油酸的存在会提升维生素B6的功能；
维生素B12促进红细胞的发育和成熟，使机体造血机能处于正常状态；
维生素C具有较强的抗氧化能力，且能促进体内蛋白的合成，预防贫血，增强肠道血管壁的弹性，防止出现消化道出血；
烟酸，能促进消化系统的健康，减轻胃肠障碍；促进血液循环，减轻腹泻现象；
叶酸，是人体在利用糖分和氨基酸时的必要物质，是机体细胞生长和繁殖所必需的物质，在体内以四氢叶酸的形式起作用。参与嘌呤、胸腺嘧啶的合成，直接影响DNA的合成；参与氨基酸之间的相互代谢转化，如丝氨酸与甘氨酸之间的转换、组氨酸转化为谷氨酸、同型半胱氨酸与蛋氨酸的互相转换等；参与血红蛋白和其他甲氨基化合物的合成，如肾上腺素、胆碱、肌酸等。
泛酸，以乙酰辅酶A的形式参加代谢过程，是二碳单位的载体，也是体内乙酰化酶的辅酶，可以帮助肠道新生细胞的形成，维持正常发育和中枢神经系统的发育；同时，泛酸具有制造抗体功能，能帮助抵抗传染病，缓和多种抗生素副作用及毒性，并有助于减轻过敏症状；
生物素，能增强机体的免疫反应和对感染的抵抗能力，稳定正常组织的溶酶体膜，维持机体的体液免疫、细胞免疫并影响一系列细胞因子的分泌；
胆碱，是一种强有机碱，是卵磷脂的组成成分，可以改善脂肪的吸收和利用，促进胃肠道平滑肌收缩，促进胃肠道蠕动；
肌醇，可以促进细胞的代谢，促进消化，增加食欲；
钙、钾、镁作为常量元素，其中，钙是人体骨骼和牙齿的重要成分，它参与人体的许多酶反应、血液凝固，维持心肌的正常收缩，抑制神经肌肉的兴奋，巩固和保持细胞膜的完整性；钾在人体内的主要作用是维持酸碱平衡，参与能量代谢以及维持神经肌肉的正常功能；镁作为酶的激活剂参与300余种酶促反应，参与骨骼的构成和生长，维持神经肌肉的兴奋性，并影响甲状旁腺激素的分泌；
铁、锌、碘、硒、铜、锰作为微量元素，参与体内蛋白质的合成，促进维生素的吸收，且可以抑制肿瘤细胞的生长，提高人体的免疫力；
化疗患者因为呕吐，维生素(维生素A、维生素D、维生素E、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、烟酸、叶酸、泛酸)和矿物质(钾、钠、镁、钙、铁、锌)的大量丢失，导致电解质失衡,所以应及时予以补充；
DHA(二十二碳六烯酸)作为一种必需脂肪酸，是神经系统细胞生长及维持的主要营养物质，也是大脑和视网膜的重要组成成分，在增强记忆与思维能力、提高智力等方面作用显著；人群流行病学研究发现，体内DHA含量高的人的心理承受力较强、智力发育指数也高；而且，DHA及其衍生物在机体中能够杀死癌细胞，为癌症的治疗提供了新的方法；
EPA(二十碳五烯酸)具有降血脂、降血压、降血糖作用，可预防和改善动脉硬化，防止高血压；
omega-3可促进中性或酸性胆固醇自粪便排出，抑制肝内脂质及脂蛋白合成，能降低血浆中胆固醇、甘油三酯、低密度脂蛋白、极低密度脂蛋白含量，增加高密度脂蛋白含量；还可以参与花生四烯酸代谢，生成前列腺素类化合物PGI3及TXA3；花生四烯酸的代谢物为前列环素和血栓素；PGI3可舒张血管及抗血小板聚集、防止血栓形成；TXA3则可使血管痉挛、促进血小板聚集和血栓形成；
磷脂酰丝氨酸可以提高大脑机能集中注意力，改善记忆力，可以缓解压力，促进用脑疲劳的人恢复平衡情绪，另外还可以帮助修复大脑损伤。
本发明还旨在提供一种化疗后辅助修复消化道粘膜的功能性食品在辅助恢复化疗后消化道功能中的应用。
本发明提供了一种化疗后辅助修复消化道粘膜的功能性食品，以功能性低聚糖、复合维生素、常量元素、微量元素和鱼油复配成功能性低聚糖，对预防化疗后便秘、腹泻、消化道出血有显著的效果，而且，本组方中，鱼油和微量元素的存在可以显著促进肠道对复合维生素的吸收，DHA、EPA、omega-3和磷脂酰丝氨酸组合，不仅可以促进神经系统的发育，还具有显著的抗癌效果，较单一组分，抗癌效果提升，同时，具有通便、修复肠道粘膜的效果；功能性低聚糖也可以促进维生素和微量元素、常量元素的吸收，所以，各组分间相互配合，协同增效，共同行使功能，最大程度地达到了修复肠粘膜和胃粘膜的功能。
综上所述，本发明提供的功能性食品涵盖多种营养成分，富含谷氨酰胺、ω-3脂肪酸、复合维生素、益生元等，经过科学匹配，增强了患者对放化疗的耐受力，提高了患者的机体免疫力，控制了急性炎性反应，调节了肠道菌群，起到了修复肠黏膜屏障功能，减少了并发症，缩短了住院时间，降低了治疗费用；而且，该功能性食品适口性较好，可在一定程度上提高患者的食欲。
附图说明
图1附图为本发明实施例5丝裂霉素对GES-1胃粘膜细胞损伤示意图；
图2附图为本发明实施例5功能性食品对GES-1胃粘膜细胞修复结果示意图；
图3附图为本发明实施例6丝裂霉素对小鼠体重影响示意图；
图4附图为本发明实施例6IHC检测结果图；
图5附图为本发明实施例6Tunel检测结果图；
图6附图为本发明实施例6ELISA检测结果图；
图7附图为本发明实施例6ZO-1蛋白表达水平图；
图8附图为本发明实施例6Ecadherin蛋白表达水平图；
图9附图为本发明实施例6β-catenin蛋白表达水平图；
图10附图为本发明实施例6Occludin蛋白表达水平图；
图11附图为本发明实施例6ZO-1 mRNA表达水平图；
图12附图为本发明实施例6E-cadherin mRNA表达水平图；
图13附图为本发明实施例6β-catenin mRNA表达水平图；
图14附图为本发明实施例6Occludin mRNA表达水平图。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种化疗后辅助修复消化道粘膜的功能性食品，包括：低聚半乳糖0.2g、水苏糖2g、低聚甘露糖0.1g、谷氨酰胺1.3g、棕榈酸视黄酯100μgRE、麦角钙化醇3.5μg、d-α-生育酚1.6mgα-TE、盐酸硫胺素1mg、核黄素-5’-磷酸钠0.25mg、烟酸吡哆醇1mg、盐酸氰钴胺0.3μg、磷酸酯镁65mg、烟酸2.2mg、叶酸70μg、泛酸1mg、生物素30μg、胆碱1mg、肌醇10mg、钙30mg、钾15mg、镁10mg、铁3.0mg、锌2.5mg、碘25μg、硒10μg、铜0.27mg、锰0.5mg、DHA60 mg、EPA75mg、omega-3150mg、磷脂酰丝氨酸7mg。
实施例2
一种化疗后辅助修复消化道粘膜的功能性食品，包括：低聚半乳糖0.3g、水苏糖0.8g、低聚甘露糖0.2g、谷氨酰胺1.0g、β-胡萝卜素215μgRE、胆钙化醇3.0μg、d-α-醋酸生育酚5.4mgα-TE、硝酸硫胺素0.65mg、核黄素0.65mg、烟酸吡哆醇0.65mg、羟钴胺0.15μg、抗坏血酸棕榈酸酯40mg、烟酸3.5mg、叶酸66μg、泛酸2.0mg、生物素21μg、胆碱7.5mg、肌醇7.5mg、钙100mg、钾12.5mg、镁25mg、铁2.5mg、锌3.0mg、碘22μg、硒14.5μg、铜0.20mg、锰0.6mg、DHA55 mg、EPA85mg、omega-3142mg、磷脂酰丝氨酸8.5mg。
实施例3
一种化疗后辅助修复消化道粘膜的功能性食品，包括：低聚半乳糖0.5g、水苏糖0.5g、低聚甘露糖0.3g、谷氨酰胺0.8g、醋酸视黄酯300μgRE、胆钙化醇2.5μg、dl-α-生育酚10mgα-TE、硝酸硫胺0.25mg、核黄素1mg、烟酸吡哆醇0.2mg、氰钴胺3μg、L-抗坏血酸钠20mg、烟酸5mg、叶酸60μg、泛酸3.5mg、生物素10μg、胆碱10mg、肌醇1mg、钙140mg、钾10mg、镁40mg、铁2.0mg、锌3.5mg、碘20μg、硒17μg、铜0.15mg、锰0.7mg、DHA50 mg、EPA90mg、omega-3135mg、磷脂酰丝氨酸10mg。
实施例1-3中，提供钙元素的原料为碳酸钙；提供钾元素的原料为葡萄糖酸钾；提供镁元素的原料为氧化镁；提供铁元素的原料为富马酸亚铁；提供锌元素的原料为硫酸锌；提供碘元素的原料为碘化钠；提供硒元素的原料为亚硒酸钠；提供铜元素的原料为硫酸铜；提供锰元素的原料为硫酸锰。
实施例1-3中的功能性食品的制备过程为：
(1)称取预定量的各原料，其中、低聚半乳糖、水苏糖、低聚甘露糖、维生素、微量元素、常量元素、EPA、omega-3、磷脂酰丝氨酸等原料预先制备成预混料；
(2)将剩余原料逐渐加入加入进行混合，混合10-30分钟，出料。
(3)上述各原料配制前及配制完成后均经过杀菌处理；营养配方的剂型包括：营养粉、营养乳剂、胶囊剂、片剂、丸剂、口服液。
实施例4急性毒性试验
选取8周龄无特殊病原体的SD大鼠进行急性毒性试验，分为9组，每组5只；
将实施例1-3制备得到的功能性食品分别悬浮于0.5％的甲基纤维素溶液中，每种功能性食品分别以1g/kg、5g/kg和10g/kg的剂量一次口服施用于每组的5只SD大鼠，观察大鼠的死亡、临床症状以及体重变化，并进行血液试验和血液生化试验，在尸检时，肉眼检查胸腹部胃肠组织的任何异常现象；
结果显示：实施例1-3所述的功能性食品未引起任何特定的临床症状、体重变化或死亡，血液试验、血液生化试验和尸检也没有变化。因此，由于直至10g/kg的剂量不会引起大鼠的任何中毒变化，可判断其半数致死量(LD50)远远大于10g/kg，实施例1-3涉及的功能性食品被评定为安全无毒物质。
实施例5实施例3的功能性食品对化疗后GES-1胃粘膜细胞的修复作用
取对数生长期的GES-1胃粘膜细胞，每孔接种细胞悬液100μL于96孔培养板中。37℃、5％CO2培养过夜。次日取出细胞板，弃上清，加入丝裂霉素20μL+功能性食品100μL，每一处理均做6复孔。对照组加入丝裂霉素20μL，另做一孔不加细胞，只加培养液(比色时用此孔调零)。外周加PBS保持细胞培养板内部水分，在37℃、5％CO2条件下培养。于培养时间结束时，依次在每孔中加入浓度为5mg/mL的MTT溶液10μL，继续孵育4h。弃去孔中培养上清液，再于每孔加入100μL DMSO充分震荡至结晶物充分溶解。在酶联免疫检测仪上选择570nm波长，测定各孔光吸收值(OD值)；结果见图1和图2。
图1结果显示，丝裂霉素显著损伤了胃粘膜细胞，降低了其生存率；图2结果显示，实施例3中的功能性食品对GES-1胃粘膜细胞增殖效果明显，可以有效提高化疗后胃粘膜细胞的存活率，抑制化疗药物对胃粘膜细胞的损伤。
实施例6验证实施例3的功能性食品对化疗后肠道粘膜细胞的促增殖作用
取Balb/c小鼠，雌性，6～8周龄，适应性饲养3～7天后，按体重随机分为正常组(10只)和荷瘤组(50只)。荷瘤组接种4T1乳腺癌细胞(1×105个/只)，建立小鼠乳腺癌模型。造模24h后各组按表1给药21天，连续21天，正常组和模型组给予等体积的生理盐水。
表1
实验过程中，每3天记录一次体重。末次给药后24h，脱臼处死各组动物，从眼眶静脉丛采集静脉血，部分置于洁净EP管中，静置后分离得到血清，用ELISA试剂盒测定脂多糖含量。同时剖取小肠约8cm(回肠结上端1cm处)，部分组织进行苏木精-伊红染色观察组织变化，并进行免疫组化实验观察小肠细胞增殖能力，原位末端脱氧核苷酸转移酶介导的dUTP缺口末端标记实验观察小肠细胞凋亡水平；另取部分组织进行免疫印迹实验检测小肠上皮连接蛋白表达水平，包括紧密连接蛋白1(ZO-1)、钙黏蛋白E(E-cadherin)、β连环蛋白(β-catenin)、闭合蛋白(Occludin)表达水平；剩下部分组织进行实时荧光定量聚合酶链式反应检测上述小肠上皮连接蛋白所对应基因表达水平。其中与正常组比较，“*”“**”分别表示p<0.05，p<0.01；与模型组比较，“#”“##”分别表示p<0.05，p<0.01；与丝裂霉素组比较，“△”“△△”分别表示p<0.05，p<0.01。
如图3所示，给药21天后，与正常组和模型组相比，丝裂霉素组小鼠体重明显下降，小肠结构发生改变，主要集中在侧肌层疏松，肠绒毛明显缩短，而与丝裂霉素组相比，联合用药组小鼠体重均有明显上升趋势，且小肠绒毛明显增加，间距明显缩短，结构得到恢复。说明实施例3中的功能性食品能缓解由丝裂霉素引起的肠道损伤症状。
IHC和Tunel检测结果表明(图4、图5)，与正常组和模型组相比，丝裂霉素组小肠组织中PCNA表达水平明显降低，细胞凋亡水平明显升高，而与丝裂霉素组相比，联合用药组PCNA表达水平明显上升而细胞凋亡水平明显下降。说明实施例3中的功能性食品可促进小肠细胞增殖并抑制凋亡，对肠道损伤有明显改善作用。
ELISA检测结果(图6)、WB分析结果(图7～10)以及RT-qPCR检测结果(图11～14)表明与正常组和模型组相比，丝裂霉素组小鼠血清中LPS含量明显上升，组织中小肠上皮连接蛋白(ZO-1、E-cadherin、β-catenin、Occludin)及其所对应基因表达水平均明显降低，而与丝裂霉素组相比，联合用药组血清LPS含量明显降低且小肠上皮连接蛋白及其所对应基因表达水平均明显上升。上述结果说明实施例3中的功能性食品可缓解由丝裂霉素引起的小肠损伤，促进小肠组织修复，恢复肠道屏障完整性。
实施例7
十名患有白血病的儿童服用实施例3中的功能性食品，血浆中营养指标的变化见表2-表6；
表2
表3
表4
表5
表6
由表2-表6可知，实施例3的功能性食品确实可以修复肠道粘膜功能，促进营养物质的吸收，重塑化疗儿童的肠道菌群结构，利于提高其抵抗力，还能在一定程度上提高白血病儿童的生存率。
除此之外，经过跟踪调查证实，本发明的功能性食品，在儿童进行骨髓移植后，也可以一直服用，无任何副作用，且可以降低抗排异药物对肝肾、肠道带来的毒副作用。
本说明书中各个实施例采用递进的方式描述，每个实施例重点说明的都是与其他实施例的不同之处，各个实施例之间相同相似部分互相参见即可。对于实施例公开的装置而言，由于其与实施例公开的方法相对应，所以描述的比较简单，相关之处参见方法部分说明即可。
对所公开的实施例的上述说明，使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的，本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下，在其它实施例中实现。因此，本发明将不会被限制于本文所示的这些实施例，而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (3)
1.一种化疗后辅助修复消化道粘膜的功能性食品，其特征在于，包括：低聚半乳糖0.2-0.5g、水苏糖0.5-2g、低聚甘露糖0.1-0.3g、谷氨酰胺0.8-1.3g、维生素A 100-300μgRE、维生素D32.5-3.5μg、维生素E 1.6-10mgα-TE、维生素B10.25-1mg、维生素B20.25-1mg、维生素B60.2-1mg、维生素B120.3-3μg、维生素C 20-65mg、烟酸2.2-5mg、叶酸60-70μg、泛酸1-3.5mg、生物素10-30μg、胆碱1-10mg、肌醇1-10mg、钙30-140mg、钾10-15mg、镁10-40mg、铁2.0-3.0mg、锌2.5-3.5mg、碘20-25μg、硒10-17μg、铜0.15-0.27mg、锰0.5-0.7mg、DHA 50-60mg、EPA 75-90mg、omega-3135-150mg、磷脂酰丝氨酸7-10mg。
2.根据权利要求1所述的一种化疗后辅助修复消化道粘膜的功能性食品，其特征在于，包括：低聚半乳糖0.3g、水苏糖0.8g、低聚甘露糖0.2g、谷氨酰胺1.0g、维生素A 215μgRE、维生素D33.0μg、维生素E 5.4mgα-TE、维生素B10.65 mg、维生素B20.65 mg、维生素B60.65 mg、维生素B120.15μg、维生素C 40mg、烟酸3.5mg、叶酸66μg、泛酸2.0mg、生物素21μg、胆碱7.5mg、肌醇7.5mg、钙100mg、钾12.5mg、镁25mg、铁2.5mg、锌3.0mg、碘22μg、硒14.5μg、铜0.20mg、锰0.6mg、DHA 55mg、EPA 85mg、omega-3142mg、磷脂酰丝氨酸8.5mg。
3.根据权利要求1-2任一所述的一种化疗后辅助修复消化道粘膜的功能性食品在辅助恢复化疗后消化道功能中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011141422.2A CN112262982A (zh) | 2020-10-22 | 2020-10-22 | 一种化疗后辅助修复消化道粘膜的功能性食品及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011141422.2A CN112262982A (zh) | 2020-10-22 | 2020-10-22 | 一种化疗后辅助修复消化道粘膜的功能性食品及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112262982A true CN112262982A (zh) | 2021-01-26 |
Family
ID=74343042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011141422.2A Pending CN112262982A (zh) | 2020-10-22 | 2020-10-22 | 一种化疗后辅助修复消化道粘膜的功能性食品及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112262982A (zh) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103609933A (zh) * | 2013-10-31 | 2014-03-05 | 湖北一半天制药有限公司 | 一种用于肿瘤患者的肠内营养乳剂 |
| CN108378377A (zh) * | 2018-05-08 | 2018-08-10 | 山东理工大学 | 宫颈癌全营养配方食品的制备方法及其应用 |
| CN108813576A (zh) * | 2018-05-08 | 2018-11-16 | 山东理工大学 | 一种胃癌营养食品及其制备方法 |
| CN108902933A (zh) * | 2018-05-08 | 2018-11-30 | 山东理工大学 | 前列腺癌全营养食品及其制备方法 |
| CN108936597A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 一种直肠癌营养食品及其制备方法 |
| CN108936595A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 结肠癌营养食品及其制备方法 |
| CN108936623A (zh) * | 2018-07-24 | 2018-12-07 | 山东圣海保健品有限公司 | 双蛋白胃癌全营养配方食品及其制备方法 |
| CN108936596A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 肺癌营养食品及其制备方法 |
| CN109645466A (zh) * | 2019-01-15 | 2019-04-19 | 吕麟亚 | 一种针对儿童肿瘤患者食用的组合物 |
| CN111513333A (zh) * | 2020-05-31 | 2020-08-11 | 上海复旦奥医医学科技有限公司 | 肺癌专用型临床营养配方食品及其制备方法 |
-
2020
- 2020-10-22 CN CN202011141422.2A patent/CN112262982A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103609933A (zh) * | 2013-10-31 | 2014-03-05 | 湖北一半天制药有限公司 | 一种用于肿瘤患者的肠内营养乳剂 |
| CN108378377A (zh) * | 2018-05-08 | 2018-08-10 | 山东理工大学 | 宫颈癌全营养配方食品的制备方法及其应用 |
| CN108813576A (zh) * | 2018-05-08 | 2018-11-16 | 山东理工大学 | 一种胃癌营养食品及其制备方法 |
| CN108902933A (zh) * | 2018-05-08 | 2018-11-30 | 山东理工大学 | 前列腺癌全营养食品及其制备方法 |
| CN108936597A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 一种直肠癌营养食品及其制备方法 |
| CN108936595A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 结肠癌营养食品及其制备方法 |
| CN108936596A (zh) * | 2018-05-08 | 2018-12-07 | 山东理工大学 | 肺癌营养食品及其制备方法 |
| CN108936623A (zh) * | 2018-07-24 | 2018-12-07 | 山东圣海保健品有限公司 | 双蛋白胃癌全营养配方食品及其制备方法 |
| CN109645466A (zh) * | 2019-01-15 | 2019-04-19 | 吕麟亚 | 一种针对儿童肿瘤患者食用的组合物 |
| CN111513333A (zh) * | 2020-05-31 | 2020-08-11 | 上海复旦奥医医学科技有限公司 | 肺癌专用型临床营养配方食品及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 姜良铎主编: "《水苏糖与健康》", 31 January 2005, 西安第四军医大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5145033B2 (ja) | Ｈｍｂ組成物及びその使用 | |
| JP5400997B2 (ja) | 哺乳動物の大腸内のガス発生及びこれに起因する腹部症状を回避又は低減するための、鉱物質及び場合によっては酢酸生成菌及び／又は酪酸生成菌からなる組成物の使用 | |
| JP4699901B2 (ja) | 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質 | |
| US20100047364A1 (en) | Nutrient System for Individualized Responsive Dosing Regimens | |
| KR20070054739A (ko) | 종합 경장 영양 조성물 | |
| JPH11508282A (ja) | 悪液質および食欲不振の予防および治療方法 | |
| KR20140022888A (ko) | 영양 조성물 | |
| CN113615831B (zh) | 一种促进溃疡性结肠炎粘膜修复的临床营养组合物及其制备方法 | |
| CN108391811A (zh) | 一种肿瘤全营养配方食品及其应用 | |
| CN105558046A (zh) | 一种用于肝病患者的特殊医学用途配方食品及其制备方法 | |
| Silk | Towards the optimization of enteral nutrition | |
| CN109090580A (zh) | 一种用于肿瘤患者的特定全营养配方食品及其制备方法 | |
| JPS58501676A (ja) | 微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用 | |
| JP2018521031A (ja) | 胃腸系運動を刺激するための薬物の製造におけるマルチビタミン組成物の使用 | |
| CN116172191A (zh) | 营养组合物及其在制备抗炎产品中的应用 | |
| JP2020503373A (ja) | 胃腸系の運動を促進する複合ビタミン組成物 | |
| NO20001717L (no) | Serotonin-inneholdende formulering for oral administrering og anvendelse av samme | |
| CN112262982A (zh) | 一种化疗后辅助修复消化道粘膜的功能性食品及其应用 | |
| WO2019106626A1 (en) | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis | |
| JP7012724B2 (ja) | 腎臓透析を受けている患者のための食餌性多量／微量栄養補給剤 | |
| CN113244246B (zh) | 一种微生物源缩醛磷脂在治疗结肠癌中的应用 | |
| ES2651903T3 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento del estado inflamatorio sistémico asociado con el accidente cerebrovascular en pacientes con disfagia | |
| EP0389667A2 (en) | Use of lecithin to restore olfaction and taste | |
| Tonozzi | Nutritional status | |
| RU2335927C2 (ru) | Обогащенные лейцином питательные композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |